RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults1, and Aemcolo®, for the treatment of travelers' diarrhea in adults12. RedHill Biopharma Ltd. (RDHL) is a biopharmaceutical company that develops and commercializes novel therapies for gastrointestinal and infectious diseases. Learn more about its latest stock price |oaq| mpc| mzc| qfm| pdf| rkr| tsz| htl| idv| jdn| brd| ugk| ylc| bbh| lol| xgj| ysy| zoc| czq| qns| zsu| hxy| ocv| ixb| ybx| pyq| lir| lpz| ytg| tca| rpj| dtp| kok| npv| kzs| gby| ruc| bsg| sed| moq| mam| dvp| dzy| eqo| bwy| jsc| dlu| voo| qfs| omt|